SupCD7 CART cells therapy (Institute Of Hematology & Blood Diseases Hospital)

N/A

Report date: 2025/09/04 20:00:08

Base Information

Drug NameSupCD7 CART cells therapy (Institute Of Hematology & Blood Diseases Hospital)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT-cell antigen CD7 modulatorsT lymphocyte replacements
TargetsT-cell antigen CD7
Therapy Area/IndicationsLeukemia, Myeloid, AcutePrecursor T-Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesInstitute Of Hematology & Blood Diseases Hospital
China Registration ClassN/A

Develop Information

Active CompaniesInstitute Of Hematology & Blood Diseases Hospital
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, AcutePrecursor T-Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A